These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 32060001

  • 1. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
    Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, Kramer J, Duan Z, Yang H, Kolluri A, Hummer AM, Torres MB, Zhu H, Hall MD, Luo X, Chen J, Wang Q, Abate-Daga D, Dropulic B, Hewitt SM, Orentas RJ, Greten TF, Ho M.
    Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C, Li K, Jiang H, Song F, Gao H, Pan X, Shi B, Bi Y, Wang H, Wang H, Li Z.
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [Abstract] [Full Text] [Related]

  • 6. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U.
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [Abstract] [Full Text] [Related]

  • 7. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.
    Pan Z, Di S, Shi B, Jiang H, Shi Z, Liu Y, Wang Y, Luo H, Yu M, Wu X, Li Z.
    Cancer Immunol Immunother; 2018 Oct; 67(10):1621-1634. PubMed ID: 30078052
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
    Wu X, Luo H, Shi B, Di S, Sun R, Su J, Liu Y, Li H, Jiang H, Li Z.
    Mol Ther; 2019 Aug 07; 27(8):1483-1494. PubMed ID: 31078430
    [Abstract] [Full Text] [Related]

  • 10. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
    Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z, Jiang H.
    J Immunol; 2019 Jul 01; 203(1):198-207. PubMed ID: 31142602
    [Abstract] [Full Text] [Related]

  • 11. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, Li Z.
    Clin Cancer Res; 2014 Dec 15; 20(24):6418-28. PubMed ID: 25320357
    [Abstract] [Full Text] [Related]

  • 12. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
    Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, Lu Q, Gao H, Jiang H, Wang H, Yuan D, Ma H, Wang H, Li Z, Zhai B.
    Clin Cancer Res; 2020 Aug 01; 26(15):3979-3989. PubMed ID: 32371538
    [Abstract] [Full Text] [Related]

  • 13. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W, Liu Y, Hu Y, Gao J.
    Sheng Wu Gong Cheng Xue Bao; 2020 May 25; 36(5):979-991. PubMed ID: 32567281
    [Abstract] [Full Text] [Related]

  • 14. Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC.
    Kolluri A, Li D, Li N, Duan Z, Roberts LR, Ho M.
    Hepatol Commun; 2023 Feb 01; 7(2):e0022. PubMed ID: 36691969
    [Abstract] [Full Text] [Related]

  • 15. IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma.
    Chen S, Gong F, Liu S, Xie Y, Ye X, Lin X, Wang X, Zheng Q, Liu Q, Sun Y.
    Clin Exp Med; 2024 Aug 28; 24(1):204. PubMed ID: 39196390
    [Abstract] [Full Text] [Related]

  • 16. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
    Meng M, Wu YC.
    J Immunol Res; 2021 Aug 28; 2021():1782728. PubMed ID: 34527749
    [Abstract] [Full Text] [Related]

  • 17. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
    Yu M, Luo H, Fan M, Wu X, Shi B, Di S, Liu Y, Pan Z, Jiang H, Li Z.
    Mol Ther; 2018 Feb 07; 26(2):366-378. PubMed ID: 29339014
    [Abstract] [Full Text] [Related]

  • 18. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma.
    Lin X, Liu Z, Dong X, Wang K, Sun Y, Zhang H, Wang F, Chen Y, Ling J, Guo Y, Xiang H, Xie Q, Zhang Y, Guo Z, Sugimura R, Xie G.
    J Transl Med; 2024 Oct 13; 22(1):929. PubMed ID: 39396988
    [Abstract] [Full Text] [Related]

  • 19. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
    Lu LL, Xiao SX, Lin ZY, Bai JJ, Li W, Song ZQ, Zhou YH, Lu B, Wu WZ.
    Cell Biol Toxicol; 2023 Dec 13; 39(6):3101-3119. PubMed ID: 37853185
    [Abstract] [Full Text] [Related]

  • 20. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, Li W, Cai C, Xu J, Zhao X.
    Cancer Immunol Res; 2019 Nov 13; 7(11):1813-1823. PubMed ID: 31484657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.